NASDAQ
BIIB
Last Price
US $216.12
KEY FIGURES
MKT CAP
$31.9B
EPS
TTM
$9.32
PEG
TTM
N/M
P/E
TTM
23.06x
P/S
TTM
3.25x
YIELD
0.00%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
7.55%
Return on equity
ROIC: 5.44%
Valuation History
23.1X
Price to Earnings
EV/EBITDA: 13.0X
Cash flow
Profit margin
-6.11%
(FY vs FY)
EBITDA Y/Y
-9.50%
(FY vs FY)
Cash flow Y/Y
-11.63%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $216.12
-67.25%
Default assumptions
EBITDA Multiple
Fair Value
Market $216.12
-43.99%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Biogen Inc. cash flow to debt ratio of 31.73% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.
Financial risk - Healthy cash flow growth.
Biogen Inc.'s free cash flow has decreased -18.48% from $2.52G last year to $2.05G, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Biogen Inc.'s debt to equity ratio is 0.35, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Biogen Inc.'s debt has decreased relative to shareholder equity from 0.40 last year to 0.35 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Biogen Inc. has a net debt to EBITDA ratio of 1.27x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Biogen Inc.'s interest coverage ratio of 5.61 indicates that earnings with good margin can cover interest payments on company debt
Financial risk - Profit margin growth.
Biogen Inc.'s profit margin has decreased (-17.47%) in the last year from 16.87% to 13.92%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Biogen Inc.'s short-term assets of $8.97G exceed its short-term liabilities of $3.35G
Decreasing performance - ROA.
Biogen Inc.'s return on assets of 4.65% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Biogen Inc.'s return on equity of 7.55%, is lower than 15.00%, indicating bad performance
Increasing performance - Earnings quality.
Biogen Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
Biogen Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Biogen Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Biogen Inc. has a free cash flow yield of 6.43%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Decreasing performance - Healthy earnings growth.
Biogen Inc.'s yearly earnings has decreased -20.76% since last year from $1.63G to $1.29G, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Biogen Inc.'s yearly revenue has increased 1.39% since last year from $9.68G to $9.81G, signaling increasing performance
Increasing performance - ROIC.
ROIC 5.44% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.
Decreasing performance - 3-year revenue CAGR.
Biogen Inc.'s 3-year revenue CAGR of -1.20% is negative, indicating declining revenue over the past 3 years
Decreasing performance - Revenue consistency.
Biogen Inc. had revenue growth in only 1.00 out of 5 years, indicating inconsistent revenue performance
Increasing performance - ROE consistency.
Biogen Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Biogen Inc. is overvalued relative to its fair value price of 70.78 based on Discounted Cash Flow model
Undervalued - Earnings yield.
Biogen Inc. has an earnings yield of 4.32%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
Biogen Inc. is overvalued relative to its fair value price of 121.05 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Biogen Inc. has an EV/EBITDA ratio of 12.98x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
Biogen Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Biogen Inc. has a price-to-book ratio of 1.70x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Biogen Inc. has a price-to-sales ratio of 3.24x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue